Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11577291 | 0.98 | TAAR1 (0.53) | TAAR1TSHRNPC1SMN1; SMN2RAB9A | |
| SCHEMBL17743347 | 0.98 | TAAR1 (0.53) | TAAR1TSHRNPC1SMN1; SMN2RAB9A | |
| SCHEMBL144588 | 0.94 | TAAR1 (0.57) | TAAR1TSHRNPC1SMN1; SMN2RAB9A | |
| SCHEMBL144122 | 0.85 | — | — | |
| SCHEMBL20146704 | 0.85 | TAAR1 (0.73) | TAAR1TSHRNPC1SMN1; SMN2RAB9A | |
| Water SCHEMBL29498409 | 0.83 | TAAR1 (0.54) | TAAR1TSHRNPC1SMN1; SMN2RAB9A | |
| SCHEMBL8571535 | 0.83 | TAAR1 (0.70) | TAAR1TSHRNPC1SMN1; SMN2RAB9A | |
| SCHEMBL7116263 | 0.83 | TAAR1 (0.70) | TAAR1TSHRNPC1SMN1; SMN2RAB9A | |
| SCHEMBL6734915 | 0.83 | TAAR1 (0.70) | TAAR1TSHRNPC1SMN1; SMN2RAB9A | |
| SCHEMBL3688383 | 0.82 | TAAR1 (0.53) | TAAR1TSHRNPC1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 509 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3268410-A1 | HEXABENZOCORONENE-BASED COMPOUND FOR ORGANIC PHOTOVOLTAIC CELLS. | Centre National de la Recherche Scientifique (C.N.R.S.) (FR) | 2018-01-17 | — | — | EP | claimed |
| WO-2016142923-A1 | HEXABENZOCORONENE-BASED COMPOUND FOR ORGANIC PHOTOVOLTAIC CELLS. | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2016-09-15 | — | — | WO | claimed |
| US-20240084308-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2024-03-14 | — | — | US | disclosed |
| US-20240034845-A1 | POLYMER PARTICLES | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2024-02-01 | — | — | US | disclosed |
| EP-3384549-B1 | SODIUM-ION ELECTROLYTE COMPOSITION | UNIV DEAKIN (AU) | 2024-01-17 | — | — | EP | disclosed |
| US-11834663-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2023-12-05 | — | — | US | disclosed |
| US-20230348674-A1 | HYDROGELS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2023-11-02 | — | — | US | disclosed |
| WO-2023190111-A1 | RAFT POLYMERIZATION REACTION SOLUTION AND RAFT POLYMERIZATION REACTION SOLUTION PRODUCTION METHOD | テクノＵＭＧ株式会社 | 2023-10-05 | — | — | WO | disclosed |
| CN-113939544-B | non-core-shell polymer particles | 悉尼大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-116615468-A | Polymer particles | 昆士兰科技大学 | 2023-08-18 | — | — | CN | disclosed |
| WO-2023121483-A1 | IMMUNOSTIMULATORY COMPOSITIONS | VICTORIA LINK LIMITED (NZ) | 2023-06-29 | — | — | WO | disclosed |
| US-5155101-A | Tricyclic compounds | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0498069-A2 | New use of peptide derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-12 | — | — | EP | disclosed |
| WO-1992012154-A1 | IMIDAZOTRIAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-07-23 | — | — | WO | disclosed |
| WO-1992003438-A1 | TRICYCLIC BENZODIAZEPINE DERIVATES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-05 | — | — | WO | disclosed |
| WO-1992002513-A1 | HETEROCYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-20 | — | — | WO | disclosed |
| US-4981847-A | Tricyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-01 | — | — | US | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| EP-0360079-A1 | Tricyclic compounds, processes for their preparation and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-03-28 | — | — | EP | disclosed |
| EP-0336230-A2 | Cyclic peptide antagonists of Substance P and Substance K | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834663-B2 | Fibrotic treatment | MMP1, ENPEP, RNPEP | TAAR1 3576/4885TSHR 2551/4885NPC1 3429/4885 |
| US-20230348674-A1 | HYDROGELS | PHYKPL, TST, PHOSPHO1 | TAAR1 2105/4885TSHR 1684/4885NPC1 4885/4885 |
| US-20240084308-A1 | FIBROTIC TREATMENT | MMP1, ENPEP, RNPEP | TAAR1 3576/4885TSHR 2551/4885NPC1 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.